CompletedPhase 2NCT00003966
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation
Studying Hepatic veno-occlusive disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Paul Richardson, MDDana-Farber Cancer Institute
- Intervention
- defibrotide(drug)
- Enrollment
- 151 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2000 – 2006
Study locations (9)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Duke Comprehensive Cancer Center, Durham, North Carolina, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Collaborators
Jazz Pharmaceuticals · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003966 on ClinicalTrials.govOther trials for Hepatic veno-occlusive disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05987124Defibrotide Dose-escalation for SOS Post-HSCTNew York Medical College
- RECRUITINGNCT06715046Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell TransplantationUniversity of Turin, Italy
- RECRUITINGNCT05090345A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).Duke University
- ACTIVE NOT RECRUITINGNANCT03865589Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction SyndromeChildren's Mercy Hospital Kansas City